Profiteering allegation against Baxium Health Science: CCI directs further investigation 

Director General of Anti-Profiteering Vs Baxium Health Science (Competition Commission of India)

The Director-General of Anti-Profiteering (DGAP) initiated an investigation into Baxium Health Science regarding potential profiteering in the sale of “Eclat Serum 30gm” after the GST rate was reduced from 28% to 18% on 15.11.2017, as per Notification No. 41/2017-Central Tax (Rate). The investigation, prompted by a reference from the Standing Committee on Anti-Profiteering, found that Baxium Health Science had raised its base prices, failing to pass on the b

Please become a Premium member. If you are already a Premium member, login here to access the full content.